Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
ONTARGET - Ongoing telmisartan alone and in combination with ramipril global endpoint trial und TRANSCEND - Telmisartan randomized assessment study in ACE-I intolerant subjects with cardiovascular disease (30 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 3: ONTARGET trial programme Abb. 4: ONTARGET - background Abb. 5: ONTARGET - background Aktuelles Bild - Abb. 6: ONTARGET - from HOPE to ONTARGET Abb. 7: ONTARGET - the HOPE study Abb. 8: HOPE study results: primary end point Abb. 9: HOPE study results: secondary end point Zum letzten Bild
Abbildung 6: ONTARGET - from HOPE to ONTARGET
Committed to involve over 23,000 patients worldwide, ONTARGET is the largest ARB clinical trial ever conducted. It reflects Boehringer Ingelheim's ongoing dedication to cardiovascular research. ONTARGET will build on the results of the landmark Heart Outcomes Prevention Evaluation (HOPE) trial, with the aim of identifying treatment strategies that will translate into improved patient outcomes. [7] 7. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
 
ONTARGET - from HOPE to ONTARGET
Vorheriges Bild Nächstes Bild   


Abbildung 6: ONTARGET - from HOPE to ONTARGET
Committed to involve over 23,000 patients worldwide, ONTARGET is the largest ARB clinical trial ever conducted. It reflects Boehringer Ingelheim's ongoing dedication to cardiovascular research. ONTARGET will build on the results of the landmark Heart Outcomes Prevention Evaluation (HOPE) trial, with the aim of identifying treatment strategies that will translate into improved patient outcomes. [7] 7. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung